The many faces of cholesterol in autosomal dominant polycystic kidney disease

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Biochemistry

Background:

• Autosomal dominant polycystic kidney disease (ADPKD) involves complex interactions between cholesterol metabolism, cardiovascular disease, and polycystin function.
• Shared and distinct mechanisms link ADPKD to broader chronic kidney disease (CKD) pathologies, particularly concerning lipid metabolism.

Purpose of the Study:

• To evaluate the efficacy of statin therapy in delaying disease progression in ADPKD.
• To explore the implications of novel lipid-lowering therapies for ADPKD management.
• To understand the role of cholesterol in polycystin trafficking and primary cilia function in ADPKD.

Main Methods:

• Review of existing literature and clinical trial data, including the pravastatin trial by Gitomer et al.
• Analysis of recent research on lipid metabolism and its connection to polycystin biology.
• Investigation into the role of cholesterol in the function of primary cilia.

Main Results:

• The pravastatin trial does not support using statins solely to slow ADPKD progression.
• Emerging lipid-lowering therapies offer potential benefits but also introduce new risks.
• Cholesterol is crucial for the proper traffic and function of polycystins within primary cilia.

Conclusions:

• Current evidence does not support statin monotherapy for ADPKD progression.
• Future therapeutic strategies targeting lipid metabolism in ADPKD require careful consideration of risks and benefits.
• Understanding cholesterol's role in polycystin function is key for developing targeted ADPKD treatments.